Capricor Therapeutics, Inc.
|Number of Estimates|
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Market Cap: 77.3 Million
Primary Exchange: NASDAQ
Shares Outstanding: 16.7 Million
Float: 16.3 Million
Sector: Health Technology
Longest drawdown: 2175 trading days
From: 2014-01-23 To: 2020-05-29
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|